News Release

Journal Article Cites HemoVoid™ in Proteomic Study of Schizophrenia

MONMOUTH JUNCTION, NJ, May 20, 2022 -- Biotech Support Group reports on a research article describing the simplicity and efficiency of their hemoglobin depletion technology for enriching blood proteins, in order to profile the proteome of schizophrenia patients relative to normal controls.

The citation is:

Wang, Jijun, et al. "The D2R-DISC1 protein complex and associated proteins are altered in schizophrenia and normalized with antipsychotic treatment." Journal of Psychiatry and Neuroscience 47.2 (2022): E134-E147.

The dopamine D2 receptor (D2R) is the main target of antipsychotic medications, but its mechanism remains unclear, though elevated levels of the D2R-Disrupted-in-schizophrenia 1 (DISC1) complex in postmortem brain tissue of patients with schizophrenia have been found. The study used coimmunoprecipitation to measure D2R-DISC1 complex levels in peripheral blood samples from patients with schizophrenia and unaffected controls, along with label-free proteomic analysis. The article states “Blood… samples underwent total protein extraction with the Hemoglobin Depletion and Protein Enrichment kit (Biotech Support Group)”, our product called HemoVoid™. The report identified proteins and pathways that were associated with antipsychotic treatment in schizophrenia, and that may also be novel targets for schizophrenia treatment.

“Through more efficient methods to measure the blood proteome – red cells, white cells, platelets and plasma, our products now contribute to understanding how these compartments cross-communicate. Those connections all play a role in normal homeostasis and in disease. This article illustrates how the blood proteome can be analyzed by LC-MS, in order to better understand schizophrenia.”, states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information on HemoVoid™, visit:

http://www.biotechsupportgroup.com/HemoVoid-Hemoglobin-Depletion-From-Erythrocytes-p/hvk.htm

For more information of all of our Hemoglobin removal products, visit:

https://www.biotechsupportgroup.com/Hemoglobin-Removal-s/312.htm

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for expanding proteomic analysis. Following a tiered business strategy, the company continues its growth in the consumable research products area. For this market, key products include: AlbuVoid™ and AlbuSorb™ PLUS for albumin & IgG depletion, Cleanascite™ for lipid adsorption, and HemogloBind™ and HemoVoid™ for hemoglobin removal. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com

For business development contact: Matthew Kuruc
732-274-2866 mkuruc@biotechsupportgroup.com